Xiaocheng Zhu

Xiaocheng Zhu

Auto-generated profile, based on publicly available information

Xiaocheng Zhu

Department of Anesthesiology, Xiangya Hospital, Central South University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HCHuan Chang
Huan Chang
CCCancan Cheng
Cancan Cheng
NZNing Zheng
Ning Zheng
HZHaiyan Zhu
Haiyan Zhu
HYHui Yang
Hui Yang
FZFan Zhang
Fan Zhang
Background: Inflammatory pain poses a significant clinical challenge, with its underlying mechanisms not yet fully elucidated. This study investigated the role of Caveolin-1 (Cav1) in inflammatory pain and elucidated its molecular mechanisms. Methods: We analyzed public databases and employed a mouse model of inflammatory pain induced by complete Freund’s adjuvant (CFA). Cav1-knockout (Cav1-/-) mice were used to evaluate Cav1’s function. The study incorporated behavioral tests, immunohistochemistry and molecular analyses. BV2 microglial cells served as the in vitro model. Results: Following CFA injection, Cav1 expression was markedly elevated in the dorsal horn of spinal cord, correlating with pain behavior and inflammatory responses. Cav1-/- mice demonstrated significantly reduced pain behavior and inflammatory responses after CFA induction. Mechanistically, Cav1 enhanced inflammation by activating the cGAS-STING pathway and inhibiting autophagy. In BV2 microglia, Cav1 overexpression increased proinflammatory cytokine expression (TNF-α, IL-1β, IL-6) while inhibiting autophagy, whereas Cav1 knockdown produced opposing effects. Conclusion: This study reveals a novel role of Cav1 in inflammatory pain, demonstrating its regulation of inflammation through modulation of the cGAS-STING pathway and autophagy. These findings advance our understanding of the pathogenesis of inflammatory pain and identify Cav1 as a potential therapeutic target.


1 December 2021 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
PDPonnie Robertlee Dolo
Ponnie Robertlee Dolo
LYLibin Yao
Libin Yao
YSYong Shao
Yong Shao
JWJason Widjaja
Jason Widjaja
CLChao Li
Chao Li
XZXiaocheng Zhu
Xiaocheng Zhu

1 August 2026 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HCHuan Chang
Huan Chang
XZXiaocheng Zhu
Xiaocheng Zhu
JCJuan Chen
Juan Chen
MCMunle Chin
Munle Chin
CZCaiqi Zhan
Caiqi Zhan
FZFan Zhang
Fan Zhang
Background: During diagnostic gastroscopy, intolerance is usually manifested as retching, coughing, and involuntary movement. Conscious analgesia relieves discomfort while patients continue to breathe spontaneously and remain partly responsive. Oxycodone, a semi-synthetic opioid, may reduce the need for deep propofol sedation. We compared an oxycodone-based conscious analgesia strategy with supplemental low-dose propofol with propofol-based deep sedation in elderly obese patients. Patients and Methods: In this prospective, single-center, open-label randomized controlled trial, 128 patients aged ≥ 65 years with a body mass index of 30– 39.9 kg/m2 undergoing elective gastroscopy were randomized 1:1 to propofol-based deep sedation (group P) or oxycodone-based conscious analgesia with supplemental low-dose propofol (group OP). The primary outcome was the incidence of hypoxemia, defined as any SpO2 reading < 90% during the procedure. Key secondary outcomes were airway interventions, hypotension, propofol consumption, and recovery time. Results: All 128 randomized patients completed the study. Hypoxemia occurred less frequently in group OP than in group P (10.94% vs 37.50%; relative risk, 0.29; 95% CI, 0.14– 0.63; P< 0.001). Group OP also required fewer airway interventions (10.94% vs 37.50%; P< 0.001), and mask-assisted ventilation was required less often (1.56% vs 32.81%; P< 0.001). Hypotension was less frequent (9.38% vs 28.13%; P=0.012), total propofol consumption was lower (0.38± 0.13 vs 1.70± 0.25 mg/kg; P< 0.001), and time to full wakefulness was shorter (3.89± 0.73 vs 8.21± 1.12 minutes; P< 0.001) in group OP. Conclusion: Compared with propofol-based deep sedation, the oxycodone-based conscious analgesia strategy was associated with a lower incidence of hypoxemia, fewer airway interventions, less hypotension, lower propofol exposure, and faster recovery. These findings reflect a comparison of two sedation strategies and do not establish improved respiratory function.

9 December 2025 in Annals of Medicine
Verified
Journal Article
Open access
XZXiaocheng Zhu
Xiaocheng Zhu
LGLizhe Guo
Lizhe Guo
NCNa Chen
Na Chen
LWLu Wang
Lu Wang
SDSisi Dai
Sisi Dai
EWE. Wang
E. Wang
Sleep fragmentation (SF) is a prevalent sleep disorder with an increased risk of cardiovascular diseases. Although epidemiological studies have shown a strong link between SF and adverse cardiac outcomes, specific central neural mechanisms through which SF exacerbates myocardial ischemia-reperfusion injury (MI/RI) are unclear. This study investigated the role of orexin receptor 1 (OX1R) in the hypothalamic paraventricular nucleus (PVN) in SF-induced aggravation of MI/RI and the underlying mechanism using a mouse model. C57BL/6 mice were subjected to chronic SF for 16 weeks before MI/RI modeling. Cardiac function was assessed by echocardiography. Sympathetic activity was evaluated based on the heart rate variability analysis. Molecular changes were evaluated by western blotting, qRT-PCR, and immunohistochemistry. The in vivo functional role of OX1R signaling was determined by administering OX1R-specific antagonist SB-334867 via stereotaxic injection into the PVN in the experimental groups of mice. SF mice exhibited significantly worse cardiac dysfunction and larger infarct areas following MI/RI compared to the controls. This was accompanied by enhanced sympathetic nerve activity and elevated catecholamine levels. Specifically, SF upregulated OX1R expression in the PVN and increased the levels of neuronal activation markers such as c-Fos. Pharmacological blockade of OX1R in the PVN significantly ameliorated SF-induced cardiac dysfunction, reduced the infarct size, and suppressed sympathetic hyperactivity post-MI/RI. SF may aggravate MI/RI through PVN OX1R-associated sympathetic hyperactivation. Pharmacological inhibition of OX1R improved cardiac outcomes, supporting the involvement of the PVN OX1R-sympathetic pathway in sleep disruption related cardiac injury.

15 March 2019 in European Urology Supplements
Verified
Journal Article
Closed access
XWX. Wang
X. Wang
AJA. Ji
A. Ji
JLJ. Liu
J. Liu
NSN. Sony
N. Sony
LWL. Wang
L. Wang
JWJ. Wang
J. Wang